Andreas Pahl

Andreas Pahl

Company: Heidelberg Pharma Research

Job title: Chief Scientific Officer

Seminars:

Antibody Targeted Amanitin Conjugates (ATAC): A New Payload Provides New Options for Cancer Therapy 2:00 pm

Discussing a new payload with a new mode of action providing new options to fight cancer The ATAC platform optimized the ADC technology for that payload HDP-101 targeting BCMA is the first ATAC which cleared IND and is now in dose escalation in myeloma patientsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.